Omalizumab biosimilar - Synermore Biologics

Drug Profile

Omalizumab biosimilar - Synermore Biologics

Alternative Names: SYN 008

Latest Information Update: 13 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Synermore Biologics
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Asthma
  • Preclinical Urticaria

Most Recent Events

  • 20 Jul 2016 Synermore Biologics completes a phase I trial Asthma in Australia (Synermore Biologics pipeline, October 2016)
  • 08 Feb 2016 Synermore Biologics plans a phase I trial in Healthy volunteers in Australia (SC) (ACTRN12616000145404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top